RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company operating in the United States, Argentina, and Hungary. It develops and commercializes products for underserved patient populations in ocular and medical aesthetics therapeutic areas. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for acquired blepharoptosis (low-lying eyelid) in adults. Formerly Osmotica Pharmaceuticals plc, it changed its name to RVL Pharmaceuticals plc in January 2022 and is headquartered in Bridgewater, New Jersey.